| scholarly article | Q13442814 |
| P50 | author | Alessandra Fabi | Q63704661 |
| Elda Tagliabue | Q39272222 | ||
| Francesca Bianchi | Q42317560 | ||
| P2093 | author name string | M Campiglio | |
| P Casalini | |||
| S Ménard | |||
| G Tabaro | |||
| V Adamo | |||
| A Balsari | |||
| A Bologna | |||
| D Giuffrida | |||
| E Ferri | |||
| E Tarenzi | |||
| E Valle | |||
| F Riccardi | |||
| G Mustacchi | |||
| M Sasso | |||
| R Aiello | |||
| R Bufalino | |||
| V Scotti | |||
| P2860 | cites work | Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial | Q43241014 |
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. | Q51066470 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. | Q54668841 | ||
| Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era | Q84097268 | ||
| Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer | Q35049854 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors | Q35808400 | ||
| Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study | Q36207305 | ||
| Oncogene addiction: setting the stage for molecularly targeted cancer therapy | Q37031755 | ||
| Activity and resistance of trastuzumab according to different clinical settings. | Q37897395 | ||
| Therapeutic targeting of B7-H1 in breast cancer. | Q37922793 | ||
| Metastatic behavior of breast cancer subtypes | Q38416421 | ||
| Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions | Q39652258 | ||
| Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
| Two mechanisms for IgG Fc-receptor-mediated phagocytosis by human neutrophils | Q41185178 | ||
| HER-2/neu signal transduction in human breast and ovarian cancer | Q41328221 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.5 Generic | Q19113746 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | SQL | Q47607 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Italy | Q38 |
| trastuzumab | Q412616 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 101-110 | |
| P577 | publication date | 2013-08-13 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study | |
| P478 | volume | 141 |
| Q37607675 | Clinical applications of mouse models for breast cancer engaging HER2/neu |
| Q91866549 | Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval |
| Q41555316 | Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies |
| Q37687943 | Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry |
| Q56341979 | Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer |
| Q55374436 | MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. |
| Q34240305 | Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study |
| Q33737058 | Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer |
| Q48102534 | Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. |
| Q47182575 | Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab |
| Q35880224 | Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer |
| Q91788781 | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients |
| Q28081124 | Treatment of early-stage HER2+ breast cancer-an evolving field |
| Q91045690 | Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016) |
| Q57192072 | Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China |
| Q36414012 | Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration |
Search more.